A recent study indicates that people who come off new weight-loss injections like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end traditional lifestyle plans.
Research printed in a leading health publication shows that while obese people frequently drop substantial amounts of their total mass while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit.
"People using these treatments must be cognizant of the potential of rapid weight regain when the therapy ends," warns researcher Dr. Susan Jebb.
This pace of regain means a return to pre-treatment mass within about a year and a half.
Comparing Treatments
The research, which reviewed 37 of studies involving over 9,000 of participants, compared the effects of GLP-1 agonists with other pills.
The team point out that individuals who lose weight through diet and exercise usually see a more gradual weight regain—around 0.1 kg a month—post-intervention.
The Reason for the Rapid Regain
Experts propose the mechanism of the jabs accounts for the accelerated weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone concentrations far above than normal may cause the body to generate a reduced amount of its endogenous GLP-1, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication means appetite is unsuppressed, making overeating far more likely."
A Lifelong Issue?
The NHS suggest the jabs for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts say that, due to the high risk of relapse, the treatment might need to be long-term.
This view is supported by pharmaceutical companies, who say that the results "underscore the persistent nature of obesity," similar to managing diseases like diabetes.
User Testimonies
Users who have discontinued the jabs report a sudden return of hunger.
"It was like a switch flipping and you're instantly extremely hungry," described a patient.
The struggle is compounded if users have not developed lasting lifestyle or habit changes during therapy.
Widespread Interest
Survey data show that a significant number of people in the UK have used weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is more common among females than men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are potent tools for weight loss, they are not a magic cure and long-term success hinges on integrated lifestyle changes.
